Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Non-24

- PMLiVE

NHS increases COVID-19 testing capacity, FDA halts foreign inspections

New measures to tackle the novel coronavirus announced across the Atlantic

- PMLiVE

J&J’s bispecific lung cancer antibody nabs FDA breakthrough status

Potential treatment for patient group with no FDA-approved drugs

- PMLiVE

FDA approves Recordati’s Cushing disease drug Isturisa

Important new treatment option for patients with rare disorder

- PMLiVE

FDA approves Allergan’s biodegradable glaucoma implant drug

Reduces intraocular pressure in glaucoma or ocular hypertension

- PMLiVE

Trevena gets second go at FDA approval for pain drug

FDA sets review completion date of 7 August 2020

- PMLiVE

Biohaven gets FDA approval for migraine drug Nurtec ODT

Becomes second drugmaker to bring an oral CGRP inhibitor to US market

- PMLiVE

Raising awareness and encouraging support on Rare Disease Day 2020

Rare Disease Day takes place on 29 February around the world

- PMLiVE

Acacia finally gets FDA okay for first product Barhemsys

Edison analyst predicts drug could reach $387m at peak

- PMLiVE

Lilly’s Cyramza narrowly clears FDA adcomm vote for first-line NSCLC

Advisory committee voted 6-5 in favour of drug

The ALS patient journey

Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...

Blue Latitude Health

- PMLiVE

Coronavirus outbreak escalation could impact drug supply chain

Concerns raised that the virus could cause shortages

- PMLiVE

Roche’s Herceptin/Perjeta fixed-dose combo filed with FDA

Final decision due by 18 October

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links